<DOC>
	<DOCNO>NCT02748213</DOCNO>
	<brief_summary>This study ass efficacy safety intravenous ( IV ) trastuzumab ( Herceptin ) IV docetaxel ( Taxotere ) , without oral capecitabine ( Xeloda ) , woman previously untreated HER2-positive advance and/or metastatic breast cancer .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Women With Human Epidermal Growth Factor Receptor ( HER ) 2-Positive Advanced and/or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm , HER2positive advance and/or metastatic breast cancer amenable curative therapy At least one measurable lesion accord RECIST Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Baseline leave ventricular ejection fraction ( LVEF ) least 50 % Pregnant , lactating , woman childbearing potential surgically sterile willing use adequate contraceptive method Previous treatment Herceptin antiHER therapy , previous chemotherapy advance metastatic disease Past medical history significant cardiac central nervous system ( CNS ) disorder Poor hematologic , renal , hepatic function Chronic corticosteroid therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>